Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,037,525

« Back to Dashboard
Patent 7,037,525 protects TRILEPTAL and is included in two NDAs. There have been two Paragraph IV challenges on Trileptal.

Protection for TRILEPTAL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-three patent family members in thirty-three countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 7,037,525

Title:Oxacarbazepine film-coated tablets
Abstract:The invention relates to formulations, e.g. film-coated tablets containing oxcarbazepine and to processes for the production of said formulations. The film-coated tablets have a tablet core comprising a therapeutically effective dose of oxacarbazepine being in a finely ground form having a mean particle size of from 4 to 12 .mu.m (median value), and a hydrophilic permeable outer coating.
Inventor(s): Schlutermann; Burkhard (Au, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/429,634
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 25th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
TABLET;ORAL021014-001Jan 14, 2000RXYesNo7,037,525*PED► subscribeY
TABLET;ORAL021014-002Jan 14, 2000RXYesNo7,037,525*PED► subscribeY
TABLET;ORAL021014-003Jan 14, 2000RXYesYes7,037,525*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: 7,037,525

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
7,037,525 May 02, 2014

Foreign Priority and PCT Information for Patent: 7,037,525

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland97/331Feb 14, 1997

International Patent Family for Patent: 7,037,525

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina011142► subscribe
Austria239481► subscribe
Australia6622298► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.